28.80MMarket Cap-2068P/E (TTM)
1.240High1.150Low65.23KVolume1.180Open1.270Pre Close77.92KTurnover0.28%Turnover RatioLossP/E (Static)24.00MShares2.35052wk High4.07P/B28.25MFloat Cap0.61152wk Low--Dividend TTM23.54MShs Float16.740Historical High--Div YieldTTM7.09%Amplitude0.531Historical Low1.194Avg Price1Lot Size
RenovoRx Stock Forum
RNXT SMA200 is $1.20, if we can hold above , that's bullish for sure IMO
But always have that protection in place for the profits !
MORE INFO BELOW 👇
https://chartingdaily.com/delivering-therapy-where-it-matters-now
Communicated disclaimer
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
5 minutes ago, 5:45 AM PST
Via GlobeNewswire
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Loc...
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the...
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform....
No comment yet